LOGIN  |  REGISTER

Agreement Signed for Acquisition of Lake Norman Regional Medical Center and Davis Regional Medical Center

February 28, 2023 | Last Trade: US$3.01 0.10 3.44
  • Services to be Sustained for the Community

MOORESVILLE, N.C., Feb. 28, 2023 /PRNewswire/ -- Novant Health has signed a definitive agreement to acquire Lake Norman Regional Medical Center, Davis Regional Medical Center and their related businesses, including physician clinic operations and outpatient services from subsidiaries of Community Health Systems, Inc.  (NYSE: CYH).

"Our shared commitments to the community will continue to anchor our efforts and plans as we deliver exceptional, patient-centered experiences; protect safety and quality; improve community health; and promote equitable access to care," said Carl S. Armato, president and CEO of Novant Health. "This unique and exciting opportunity to extend Novant Health's regional delivery network to new communities also creates opportunities for medical education, research and innovation."

The transaction is subject to regulatory approvals and is expected to close later this year.

"Novant Health has a demonstrated commitment to delivering quality care to the patients they serve across the communities they serve," said Matthew Littlejohn, Chief Executive Officer of Lake Norman Regional Medical Center and Davis Regional Medical Center. "Our tradition of serving the community with medical services close to home will be enhanced thanks to the dedication and skill of our medical staff and employees."

Once the transaction is complete, Novant Health will continue working with employees, members of the medical staff, and other stakeholders to deliver quality care close to home.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page